Wellington Partners Maintains Medtech Interests With New €210M Eurocentric Fund WPLS-V

While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.

Euro currency
Half The New €210m WPLS-V Fund Are Earmarked For Medtech • Source: Shutterstock

European medtech companies, especially ones in German-speaking nations, have a new well to draw from as Wellington Partners, the German venture capitalist, has closed its fifth fund at an over-subscribed €210m ($234m). Like its predecessor funds, Wellington Partners Life Science Fund V (WPLS-V) will primarily target European opportunities, although some allocations can be made in select North American and Asian businesses, across the medical life sciences spectrum including biopharma platforms, therapeutics, diagnostics, medical devices and digital health.

“We will continue to concentrate on investments in private companies from early-stage through to growth stage. We put emphasis on advanced phases of development, at a stage where the technological...

More from Financing

More from Business